Filtered By:
Source: Health News from Medical News Today
Drug: Pradaxa

This page shows you your search results in order of date.

Order by Relevance | Date

Total 2 results found since Jan 2013.

Remember to weigh up risks and benefits of new PBS-listed anticoagulants
NPS MedicineWise is reiterating safety messages around the newer anticoagulants dabigatran (Pradaxa) and apixaban (Eliquis) following their PBS listing for preventing stroke on 1 September 2013 - and again for rivaxabaran (Xarelto) which was PBS listed in August for the same purpose. These medicines will be subsidised by the Pharmaceutical Benefits Scheme (PBS) for preventing stroke in people with non-valvular atrial fibrillation, and may offer alternatives for some people...
Source: Health News from Medical News Today - September 4, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

Weigh Risks And Benefits Of Old And New Oral Anticoagulants
NPS MedicineWise is urging health professionals to weigh the risks and benefits of oral anticoagulant therapies in people with non-valvular atrial fibulation (AF) following the Pharmaceutical Benefits Advisory Committee (PBAC) recommendation that newer oral anticoagulants (NOACs) be listed on the Pharmaceutical Benefits Scheme (PBS). Following an extensive review of NOACs over the past two years, PBAC has now recommended that dabigatran (Praxada), rivaroxaban (Xarelto), and apixaban (Eliquis) be subsidised under the scheme for stroke prevention in non-valvular AF...
Source: Health News from Medical News Today - May 1, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news